Haptenation of Macrophage Migration Inhibitory Factor: A Potential Biomarker for Contact Hypersensitivity

被引:4
|
作者
Ndreu, Lorena [1 ]
Sasse, Samantha [1 ]
Karlberg, Ann-Therese [2 ]
Karlsson, Isabella [1 ]
机构
[1] Stockholm Univ, Dept Environm Sci, Stockholm, Sweden
[2] Univ Gothenburg, Dept Chem & Mol Biol, Dermatochem, Gothenburg, Sweden
来源
FRONTIERS IN TOXICOLOGY | 2022年 / 4卷
基金
瑞典研究理事会;
关键词
allergic contact dermatitis (ACD); biomarkers; contact hypersensitivity (CHS); high resolution mass spectrometry (HRMS); macrophage migration inhibitory factor (MIF); tetramethylrhodamine isothiocyanate (TRITC); in vivo skin exposure; murine; HUMAN SERUM-ALBUMIN; LYMPH-NODE ASSAY; FACTOR MIF; COVALENT MODIFICATION; RHEUMATOID-ARTHRITIS; PROTEIN HAPTENATION; FACTOR EXPRESSION; CURRENT KNOWLEDGE; DENDRITIC CELLS; BINDING-SITES;
D O I
10.3389/ftox.2022.856614
中图分类号
R99 [毒物学(毒理学)];
学科分类号
100405 ;
摘要
The immunological response in contact hypersensitivity is incited by small electrophilic compounds, known as haptens, that react with endogenous proteins after skin absorption. However, the identity of hapten-modified proteins seen as immunogenic remains as yet largely unknown. In a recent study, we have for the first time identified a hapten-modified protein in the local lymph nodes of mice treated topically with the model hapten tetramethylrhodamine isothiocyanate (TRITC). The TRITC modification was located on the N-terminal proline of the protein macrophage migration inhibitory factor (MIF). The focus of the current study was to investigate the presence of the same hapten-protein conjugate in blood samples from mice treated topically with TRITC. Furthermore, TRITC modifications of the two major blood proteins, namely hemoglobin (Hb) and albumin (Alb), as well as TRITC modifications of MIF other than the N-terminal proline, were examined. Following incubation with different molar ratios of TRITC, a proteomic approach was applied to characterize conjugate formation of the three aforementioned proteins, using high resolution mass spectrometry (HRMS). The targeted screening of the TRITC-treated mice blood and lymph node samples for these sites led to the identification of only the same TRITC-MIF conjugate previously detected in the lymph nodes. No Hb and Alb conjugates were detected. Quantification of both the TRITC-modified and unmodified N-terminal peptide of MIF in blood and lymph node samples gave interesting insights of MIF's role in murine contact hypersensitivity. Incubation of MIF with four different haptens encompassing different reactivity mechanisms and potencies, showed adduct formation at different amino acid residues, suggesting that MIF can be the preferred target for a wide variety of haptens. The present study provides essential progress toward understanding of hapten-protein conjugate formation in contact hypersensitivity and identifies hapten-modified MIF as a potential biomarker for this condition. Further investigation of MIF as a target protein can be a next step to determine if MIF is a biomarker that can be used to develop better diagnostic tools and targeted therapeutics for individuals with allergic contact dermatitis.
引用
收藏
页数:16
相关论文
共 50 条
  • [31] Roles of macrophage migration inhibitory factor in cartilage tissue engineering
    Fujihara, Yuko
    Hikita, Atsuhiko
    Takato, Tsuyoshi
    Hoshi, Kazuto
    JOURNAL OF CELLULAR PHYSIOLOGY, 2018, 233 (02) : 1490 - 1499
  • [32] Spinal Macrophage Migration Inhibitory Factor Is a Major Contributor to Rodent Neuropathic Pain-like Hypersensitivity
    Wang, FuZhou
    Xu, ShiQin
    Shen, XiaoFeng
    Guo, XiRong
    Peng, YuZhu
    Yang, Jie
    ANESTHESIOLOGY, 2011, 114 (03) : 643 - 659
  • [33] Covalent Isothiocyanate Inhibitors of Macrophage Migration Inhibitory Factor as Potential Colorectal Cancer Treatments
    Putha, Lohitha
    Kok, Liang K.
    Fellner, Matthias
    Rutledge, Malcolm T.
    Gamble, Allan B.
    Wilbanks, Sigurd M.
    Vernall, Andrea J.
    Tyndall, Joel D. A.
    CHEMMEDCHEM, 2024, 19 (21)
  • [34] Biochemical and Immunological Characterization of Toxoplasma gondii Macrophage Migration Inhibitory Factor
    Sommerville, Caroline
    Richardson, Julia M.
    Williams, Roderick A. M.
    Mottram, Jeremy C.
    Roberts, Craig W.
    Alexander, James
    Henriquez, Fiona L.
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2013, 288 (18) : 12733 - 12741
  • [35] Increased density of macrophage migration inhibitory factor (MIF) in tuberculosis granuloma
    Wang, Decheng
    Zhou, Wenjiang
    Lu, Shuihua
    Wang, Qingnan
    Feng, Yanling
    Zhu, Guofeng
    Li, Liang
    Song, Yanzheng
    Gao, Qian
    EXPERIMENTAL AND MOLECULAR PATHOLOGY, 2012, 93 (02) : 207 - 212
  • [36] Macrophage Migration Inhibitory Factor (MIF) Drives Murine Psoriasiform Dermatitis
    Bezdek, Siegfried
    Leng, Lin
    Busch, Hauke
    Mousavi, Sadegh
    Rades, Dirk
    Dahlke, Markus
    Zillikens, Detlef
    Bucala, Richard
    Sadik, Christian D.
    FRONTIERS IN IMMUNOLOGY, 2018, 9
  • [37] The Proinflammatory and Proangiogenic Macrophage Migration Inhibitory Factor Is a Potential Regulator in Proliferative Diabetic Retinopathy
    Abu El-Asrar, Ahmed M.
    Ahmad, Ajmal
    Siddiquei, Mohammad Mairaj
    De Zutter, Alexandra
    Allegaert, Eef
    Gikandi, Priscilla W.
    De Hertogh, Gert
    Van Damme, Jo
    Opdenakker, Ghislain
    Struyf, Sofie
    FRONTIERS IN IMMUNOLOGY, 2019, 10
  • [38] Macrophage migration inhibitory factor as a diagnostic and predictive biomarker in sepsis: meta-analysis of clinical trials
    Toldi, Janos
    Nemeth, David
    Hegyi, Peter
    Molnar, Zsolt
    Solymar, Margit
    Farkas, Nelli
    Alizadeh, Hussain
    Rumbus, Zoltan
    Pakai, Eszter
    Garami, Andras
    SCIENTIFIC REPORTS, 2021, 11 (01)
  • [39] Macrophage migration inhibitory factor: A noval biomarker upregulates in myasthenia gravis and correlates with disease severity and relapse
    Huang, Xiaoyu
    Li, Hao
    Zhang, Zhouao
    Wang, Zhouyi
    Du, Xue
    Zhang, Yong
    CYTOKINE, 2024, 175
  • [40] Macrophage migration inhibitory factor: A key cytokine in RA, SLE and atherosclerosis
    Santos, Leilani L.
    Morand, Eric F.
    CLINICA CHIMICA ACTA, 2009, 399 (1-2) : 1 - 7